1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Recalls

Q4 Recalls Snapshot: Recalled Devices, Units Drop

 
• By Shawn M. Schmitt

Good news for industry: The number of product recalls initiated by device makers and the number of recalled device units both dropped in the fourth quarter of 2021. Check out our Q4 recalls infographic.

Q4 Device Recalls
• Source: Shutterstock

It’s good news for industry as the number of medical device recalls initiated by manufacturers and the number of recalled device units both dropped in the fourth quarter of 2021. Q4’s 217 recalls represent a decrease of 8% from the previous quarter, which saw 235 products recalled. Even better, recalled units plummeted from 372,215,986 in Q3 to 11,554,012 in Q4, a whopping 97% decrease. Interestingly, problems with mislabeling were the top reason for recalls in Q4. That’s notable because software troubles have been the leading cause of recalls for 21 of the last 23 quarters, Sedgwick Brand Protection says in its most recent quarterly recalls index.

Get a PDF of this infographic here.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Recalls

FDA Rebukes Four Companies, Including One Overseas, For Procedural Failures

 
• By Brian Bossetta

The US FDA’s device center sent warning letters to three domestic device manufacturers and one German firm for failing to adhere to protocol on several issues.

California Medtech Firms Resolve Patent Dispute Over Delivery Catheters

 
• By Brian Bossetta

Route 92 says it has reached a settlement with Q’Apel Medical over patent claims concerning its Tenzing delivery catheters.

Q’Apel Medical Recalls, Discontinues Stroke Therapy System After FDA Warning Letter, Class I Designation

 
• By Brian Bossetta

Q’Apel Medical has pulled its aspiration system for stroke thrombectomy from the market after concerns raised by the US FDA in a February warning letter.

Makary Proposes Combined Adverse Event Reporting Systems In Megyn Kelly Interview

 
• By Sarah Karlin-Smith

In discussing FDA’s adverse event monitoring, Makary also seemed to falsely imply the agency did not fully investigate the myocarditis signal with COVID-19 vaccines.

More from Policy & Regulation

Get Ready For International Harmonization Before Approaching QMSR Deadline, Says Regulatory Expert

 
• By Brian Bossetta

During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.

UK Take Care! Regulatory And Market Access Reforms Must Not Shut Out Medtech Growth

 
• By Ashley Yeo

Speakers at a recent UK medtech outlook conference voiced optimism about the sector’s prospects, but warned that cost burdens, over-regulation and lengthy processes will impede the capacity of local SMEs to innovate. Only 10% of NHS procured medtech comes from UK manufacturers.

Zika Virus Test Among 4 New FDA Device Classifications

 
• By Elizabeth Orr

The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel